$50
3.52%
Downside
Day's Volatility :4.21%
Upside
0.71%
60.39%
Downside
52 Weeks Volatility :67.85%
Upside
18.84%
Period | Merus Nv | Sector (Health Care) | Index (Russel 2000) |
---|---|---|---|
3 Months | -5.48% | 5.1% | 0.0% |
6 Months | 6.13% | 4.9% | 0.0% |
1 Year | 110.35% | 16.6% | 0.0% |
3 Years | 89.9% | 13.2% | -22.3% |
Market Capitalization | 3.4B |
Book Value | $11.01 |
Earnings Per Share (EPS) | -2.89 |
PEG Ratio | 0.0 |
Wall Street Target Price | 87.62 |
Profit Margin | 0.0% |
Operating Margin TTM | -877.99% |
Return On Assets TTM | -19.62% |
Return On Equity TTM | -33.39% |
Revenue TTM | 35.2M |
Revenue Per Share TTM | 0.61 |
Quarterly Revenue Growth YOY | -30.0% |
Gross Profit TTM | -107.8M |
EBITDA | -194.6M |
Diluted Eps TTM | -2.89 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | -3.1 |
EPS Estimate Next Year | -3.63 |
EPS Estimate Current Quarter | -0.77 |
EPS Estimate Next Quarter | -0.76 |
What analysts predicted
Upside of 75.24%
FY18 | Y/Y Change | |
---|---|---|
Revenue | 36.0M | ↑ 141.72% |
Net Income | -27.8M | ↓ 68.34% |
Net Profit Margin | -77.17% | ↑ 512.02% |
FY19 | Y/Y Change | |
---|---|---|
Revenue | 31.1M | ↓ 13.46% |
Net Income | -55.2M | ↑ 98.66% |
Net Profit Margin | -177.15% | ↓ 99.98% |
FY20 | Y/Y Change | |
---|---|---|
Revenue | 29.9M | ↓ 3.82% |
Net Income | -85.5M | ↑ 55.05% |
Net Profit Margin | -285.59% | ↓ 108.44% |
FY21 | Y/Y Change | |
---|---|---|
Revenue | 49.1M | ↑ 64.0% |
Net Income | -66.8M | ↓ 21.86% |
Net Profit Margin | -136.06% | ↑ 149.53% |
FY22 | Y/Y Change | |
---|---|---|
Revenue | 41.6M | ↓ 15.32% |
Net Income | -131.2M | ↑ 96.35% |
Net Profit Margin | -315.48% | ↓ 179.42% |
FY23 | Y/Y Change | |
---|---|---|
Revenue | 43.9M | ↑ 5.68% |
Net Income | -154.9M | ↑ 18.1% |
Net Profit Margin | -352.56% | ↓ 37.08% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Revenue | 13.5M | ↑ 26.56% |
Net Income | -39.7M | ↓ 51.52% |
Net Profit Margin | -294.4% | ↑ 474.14% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Revenue | 10.5M | ↓ 22.39% |
Net Income | -32.0M | ↓ 19.4% |
Net Profit Margin | -305.78% | ↓ 11.38% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Revenue | 11.0M | ↑ 5.32% |
Net Income | -23.0M | ↓ 28.16% |
Net Profit Margin | -208.57% | ↑ 97.21% |
Q4 FY23 | Q/Q Change | |
---|---|---|
Revenue | 8.9M | ↓ 18.98% |
Net Income | -60.2M | ↑ 161.4% |
Net Profit Margin | -672.93% | ↓ 464.36% |
Q1 FY24 | Q/Q Change | |
---|---|---|
Revenue | 7.9M | ↓ 11.75% |
Net Income | -34.5M | ↓ 42.72% |
Net Profit Margin | -436.76% | ↑ 236.17% |
Q2 FY24 | Q/Q Change | |
---|---|---|
Revenue | 7.3M | ↓ 7.06% |
Net Income | -50.0M | ↑ 45.23% |
Net Profit Margin | -682.52% | ↓ 245.76% |
FY18 | Y/Y Change | |
---|---|---|
Total Assets | 250.0M | ↑ 5.87% |
Total Liabilities | 144.9M | ↓ 18.91% |
FY19 | Y/Y Change | |
---|---|---|
Total Assets | 263.4M | ↑ 5.37% |
Total Liabilities | 132.1M | ↓ 8.83% |
FY20 | Y/Y Change | |
---|---|---|
Total Assets | 231.2M | ↓ 12.21% |
Total Liabilities | 129.0M | ↓ 2.36% |
FY21 | Y/Y Change | |
---|---|---|
Total Assets | 456.6M | ↑ 97.48% |
Total Liabilities | 140.4M | ↑ 8.88% |
FY22 | Y/Y Change | |
---|---|---|
Total Assets | 376.5M | ↓ 17.53% |
Total Liabilities | 129.5M | ↓ 7.77% |
FY23 | Y/Y Change | |
---|---|---|
Total Assets | 458.5M | ↑ 21.76% |
Total Liabilities | 102.2M | ↓ 21.11% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 338.5M | ↓ 10.1% |
Total Liabilities | 121.0M | ↓ 6.56% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 363.6M | ↑ 7.42% |
Total Liabilities | 106.2M | ↓ 12.21% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 492.2M | ↑ 35.36% |
Total Liabilities | 98.8M | ↓ 6.99% |
Q4 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 458.5M | ↓ 6.85% |
Total Liabilities | 102.2M | ↑ 3.39% |
Q1 FY24 | Q/Q Change | |
---|---|---|
Total Assets | 498.1M | ↑ 8.63% |
Total Liabilities | 148.6M | ↑ 45.51% |
Q2 FY24 | Q/Q Change | |
---|---|---|
Total Assets | 892.2M | ↑ 79.13% |
Total Liabilities | 145.5M | ↓ 2.14% |
FY18 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -46.3M | ↑ 3.21% |
Investing Cash Flow | -25.2M | ↓ 39.54% |
Financing Cash Flow | 59.0M | ↓ 73.59% |
FY19 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -63.0M | ↑ 36.09% |
Investing Cash Flow | 24.2M | ↓ 196.05% |
Financing Cash Flow | 74.2M | ↑ 25.79% |
FY20 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -79.9M | ↑ 26.73% |
Investing Cash Flow | -1.5M | ↓ 106.15% |
Financing Cash Flow | 39.5M | ↓ 46.76% |
FY21 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -59.6M | ↓ 25.37% |
Investing Cash Flow | -146.6M | ↑ 9766.96% |
Financing Cash Flow | 282.0M | ↑ 613.45% |
FY22 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -149.9M | ↑ 151.39% |
Investing Cash Flow | 2.8M | ↓ 101.91% |
Financing Cash Flow | 58.7M | ↓ 79.17% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -36.7M | ↑ 20.42% |
Investing Cash Flow | -24.5M | ↓ 2964.25% |
Financing Cash Flow | 217.0K | ↓ 200.93% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -41.6M | ↑ 13.18% |
Investing Cash Flow | -24.5M | ↑ 0.0% |
Financing Cash Flow | 66.0M | ↑ 30299.54% |
Sell
Neutral
Buy
Merus Nv is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.
Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
---|---|---|---|---|---|
![]() Merus Nv | 2.04% | 6.13% | 110.35% | 89.9% | 203.03% |
![]() Regeneron Pharmaceuticals, Inc. | 5.97% | 16.25% | 37.11% | 69.18% | 305.56% |
![]() Novo Nordisk A/s | 9.99% | -3.52% | 34.24% | 158.74% | 417.73% |
![]() Alnylam Pharmaceuticals, Inc. | -5.15% | 64.67% | 22.72% | 31.08% | 198.44% |
![]() Vertex Pharmaceuticals Incorporated | 0.45% | 14.0% | 36.06% | 143.5% | 167.72% |
Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
---|---|---|---|---|---|---|---|---|
![]() Merus Nv | NA | NA | 0.0 | -3.1 | -0.33 | -0.2 | NA | 11.01 |
![]() Regeneron Pharmaceuticals, Inc. | 29.93 | 29.93 | 1.54 | 45.05 | 0.17 | 0.08 | NA | 261.41 |
![]() Novo Nordisk A/s | 44.01 | 44.01 | 1.98 | 3.44 | 0.89 | 0.23 | 0.01 | 25.24 |
![]() Alnylam Pharmaceuticals, Inc. | NA | NA | -0.49 | -2.55 | -15.01 | 0.02 | NA | -0.02 |
![]() Vertex Pharmaceuticals Incorporated | 32.84 | NA | 0.57 | 0.32 | -0.03 | 0.13 | NA | 57.26 |
Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
---|---|---|---|---|---|
![]() Merus Nv | Buy | $3.4B | 203.03% | NA | 0.0% |
![]() Regeneron Pharmaceuticals, Inc. | Buy | $124.7B | 305.56% | 29.93 | 32.04% |
![]() Novo Nordisk A/s | Buy | $585.3B | 417.73% | 44.01 | 34.84% |
![]() Alnylam Pharmaceuticals, Inc. | Buy | $32.3B | 198.44% | NA | -3.11% |
![]() Vertex Pharmaceuticals Incorporated | Buy | $120.9B | 167.72% | 32.84 | -4.74% |
Insights on Merus Nv
Revenue is down for the last 4 quarters, 11.03M → 7.33M (in $), with an average decrease of 12.6% per quarter
Netprofit is down for the last 2 quarters, -34.45M → -50.04M (in $), with an average decrease of 45.2% per quarter
FMR Inc
RTW INVESTMENTS, LLC
COMMODORE CAPITAL LP
Deerfield Management Co
Federated Hermes Inc
Samlyn Capital, LLC
Merus Nv’s price-to-earnings ratio stands at None
Read Moremerus is developing best-in-class therapeutics to treat and potentially cure cancer patients. our most advanced development programs use the biclonics® format. biclonics® are capable of simultaneously attacking tumors in multiple ways. for example by activating the immune system to kill tumor cells and directly inhibiting tumor cell growth and survival pathways.
Organization | Merus Nv |
Employees | 172 |
CEO | Dr. Sven Ante Lundberg M.D. |
Industry | Health Technology |